7726-11-6Relevant articles and documents
Kinetics of the Reactions of the Formyl Radical with Oxygen, Nitrogen Dioxide, Chlorine, and Bromine
Timonen, Raimo S.,Ratajczak, Emil,Gutman, David
, p. 651 - 655 (1988)
The gas-phase kinetics of the reactions of HCO with four molecules (O2, NO2, Cl2, and Br2) have been studied as a function of temperature in a tubular reactor coupled to a photoionization mass spectrometer.Rate constants for each reaction were determined at a minimum of five temperatures to obtain Arrhenius parameters (k=A exp(-Ea/RT)).The results obtained are as follows (the numbers in the brackets are log A/(cm3 molecule-1 s1-), Ea/(kJ mol-1), and the temperature ranges covered): HCO+O2 ; HCO+NO2 ; HCO+Cl2 ; HCO+Br2 .The reactivity of HCO was found to be between that of CH3 and C2H5 in the reactions of these radicals with Cl2 and Br2, which is consistent with proposed correlations of reactivity in exothermic reactions based on free-radical ionization potentials.
The UV absorption spectra of CH2Br and CH2BrO2 and the reaaction kinetics of CH2BrO2 with itself and with HO2 at 298 K
Villenave, Eric,Lesclaux, Robert
, p. 376 - 384 (1995)
The UV absorption spectra of bromomethyl (CH2Br) and bromomethylperoxy (CH2BrO2) radicals have been determined using the flash photolysis technique.CH2Br exhibits the typical absorption band of halomethyl radicals, peaking near 230 nm, and CH2BrO2 exhibits the typical broad absorption of peroxy radicals, with a maximum at 240 nm.Rate coefficients were determined at 298 K for the self-reaction (CH2BrO2 + CH2BrO2 2 CH2BrO + O2 (3), k3 = (1.05 +/- 0.4)10-12 cm3 molecule-1 s-1) and for the reaction with HO2 (CH2BrO2 + HO2 products (5), k5 = (6.7 +/- 3.8)10-12 cm3 molecule-1 s-1).As for fluorine and chlorine substitution, bromine substitution enhances the rate constant of the self-reaction, compared to that of the methylperoxy radical, whereas it does not significantly change the rate constant for the reaction with HO2.
Kinetics of the brominated alkyl radical (CHBr2, CH 3CHBr) reactions with NO2 in the temperature range 250-480 K
Rissanen, Matti P.,Eskola, Arkke J.,Timonen, Raimo S.
, p. 767 - 777 (2013/01/15)
The gas-phase kinetics of CHBr2 + NO2 and CH 3CHBr + NO2 reactions have been studied in direct time resolved measurements using a tubular flow reactor coupled to a photoionization mass spectrometer. The radicals were generated by pulsed laser photolysis of bromoform and 1,1-dibromoethane at 248 nm. The subsequent decays of the radical concentrations were monitored as a function of [NO2] under pseudo-first-order conditions. The rate coefficients of both reactions are independent of bath gas (He) pressure and display negative temperature dependence under the conditions of 2-6 Torr pressure (He) and 250-480 K. The obtained bimolecular rate coefficients are k(CHBr2 + NO2) = (9.8 ± 0.4) × 10-12 (T/300 K) -1.65 ± 0.18 cm3 s-1 (288-483 K) and k(CH3CHBr + NO2) = (2.27 ± 0.06) × 10 -11 (T/300 K)-1.28 ± 0.11 cm3 s -1 (250-483 K), with the uncertainties given as one standard error. Estimated overall uncertainties in the measured bimolecular reaction rate coefficients are ±25%. The reaction products identified were CBr 2O for the CHBr2 + NO2 reaction and CHBrO and CH3CHO with minor amounts of CH3 for the CH 3CHBr + NO2 reaction, respectively. 2012 Wiley Periodicals, Inc. Int J Chem Kinet 44: 767-777, 2012 Copyright
Estrogen receptor modulators
-
, (2008/06/13)
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restinosis, gynacomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.
Hepatitis C inhibitor tri-peptides
-
, (2008/06/13)
Disclosed herein are compounds of formula (1): wherein R1is hydroxy or NHSO2R1Awherein R1Ais (C1-8)alkyl, (C3-7)cycloalkyl or {(C1-6)alkyl-(C3-7)cycloalkyl}, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O—(C1-6)alkyl, amido, amino or phenyl, or R1Ais C6or C10aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C1-6)alkyl, O—(C1-6) alkyl, amido, amino or phenyl; R2is (C4-6)cycloalkyl; R3is t-butyl or (C5-6) cycloalkyl and R4is (C4-6)cycloalkyl; or a pharmaceutically acceptable salt thereof. The compounds are useful as inhibitors of HCV NS3 protease.
Hepatitis C inhibitor tri-peptides
-
, (2008/06/13)
Disclosed herein are compounds of formula (1): wherein Ris hydroxy or NHSO2Rwherein Ris (C1-8)alkyl, (C3-7)cycloalkyl or {(C1-6)alkyl-(C3-7)cycloalkyl}, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O-(C1-6)alkyl, amido, amino or phenyl, or Ris C6 or C10 aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C1-6)alkyl, O-(C1-6) alkyl, amido, amino or phenyl; Ris (C4-6)cycloalkyl; Ris t-btuyl or (C5-6) cycloalkyl and Ris (C4-6)cycloalkyl; or a pharmaceutically acceptable salt thereof. The compounds are useful as inhibitors of HCV NS3 protease.
Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof
-
, (2008/06/13)
The invention concerns products of formula (I) wherein: R1 represents in particular —C(O)—R5, —SO2—R5 or —C(O)—NR6R5, R2 and R7 are such that either R7 represents a hydrogen atom and R2 is such that the group (a) represents the radical of a natural or non-natural amino acid, or R2 and R7 form together a cycle with the nitrogen and carbon atom whereto they are bound, R3 represents in particular the radical —CH═N2 or —CH2-L—R4, R4 represents in particular a linear or branched alkyl radical, and their additive salts with mineral or organic acids or with mineral or organic bases of said products of formula (I). The invention also concerns the method for preparing said products and their use as medicines.
Macrocyclic peptides active against the hepatitis C virus
-
, (2008/06/13)
The present invention covers macrocyclic compounds of formula I active in-vitro and in cellular assays against the NS3 protease of the hepatitis C virus. wherein W, R21, R22, R3, R4, D and A are as defined herein, or a pharmaceutically acceptable salts or ester thereof.
Macrocyclic peptides active against the hepatitis C virus
-
, (2008/06/13)
Compounds of formula I: wherein R1 is hydroxy or NHSO2R1A wherein R1A is (C1-8)alkyl, (C3-7)cycloalkyl or {(C1-6)alkyl-(C3-7)cycloalkyl}, which are all optionally substituted from 1 to 3 times with halo, cyano, nitro, O(C1-6)alkyl, amido, amino or phenyl, or R1A is C6 or C10 aryl which is optionally substituted from 1 to 3 times with halo, cyano, nitro, (C1-6)alkyl, O(C1-6)alkyl, amido, amino or phenyl; R2 is (C5-6)cycloalkyl and R3 is cyclopentyl; or a pharmaceutically acceptable salt thereof, useful as inhibitors of the HCV NS3 protease.
Viral polymerase inhibitors
-
, (2008/06/13)
A compound of the formula I: wherein: X is CH or N; Y is O or S; Z is OH, NH2, NMeR3, NHR3; OR3 or 5- or 6-membered heterocycle, having 1 to 4 heteroatoms selected from 0, N and S, said heterocycle being optionally substituted with from 1 to 4 substituents; A is N, COR7 or CR5, wherein R5 is H, halogen, or (C1-6) alkyl and R7 is H or (C1-6 alkyl), with the proviso that X and A are not both N; R6 is H, halogen, (C1-6 alkyl) or OR7, wherein R7 is H or (C1-6 alkyl); R1 is selected from the group consisting of 5- or 6-membered heterocycle having 1 to 4 heteroatoms selected from O, N, and S, phenyl, phenyl(C1-3)alkyl, (C2-6)alkenyl, phenyl(C2-6)alkenyl, (C3-6)cycloalkyl, (C1-6)alkyl, CF3, 9- or 10-membered heterobicycle having 1 to 4 heteroatoms selected from O, N and S, wherein said heterocycle, phenyl, phenyl(C2-6)alkenyl and phenyl(C1-3)alkyl), alkenyl, cycloalkyl, (C1-6)alkyl, and heterobicycle are all optionally substituted with from 1 to 4 substituents R2 is selected from (C1-6)alkyl, (C3-7)cycloalkyl, (C3-7)cycloalkyl(C1-3)alkyl, (C6-10)bicycloalkyl, adamantyl, phenyl, and pyridyl, all of which is optionally substituted with from1 to 4 substituents; R3 is selected from H, (C1-6)alkyl, (C3-6)cycloalkyl, (C36)cycloalkyl(C1-6)alkyl, (C6-10)aryl, (C6-10)aryl(C1-6)alkyl, (C2-6)alkenyl, (C3-6)cycloalkyl(C2-6)alkenyl, (C6-10)aryl(C2-6)alkenyl, N{(C1-6)alkyl}2, NHCOO(C1-6)alkyl(C6-10)aryl, NHCO(C6-10)aryl, (C1-6)alkyl-5- or 10-atom heterocycle, having 1 to 4 heteroatoms selected from O, N and S, and 5- or 10-atom heterocycle having 1 to 4 heteroatoms selected from O, N and S; wherein said alkyl, cycloalkyl, aryl, alkenyl and heterocycle are all optionally substituted with from 1 to 4 substituents; n is zero or 1; or a detectable derivative or salt thereof. The compounds of the invention may be used as inhibitors of hepatitis C virus replication. The invention further provides a method for treating or preventing hepatitis C virus infection.
